Targeting the B-Cell Lymphoma/Leukemia 2 Family in Cancer
摘要：
The B-cell lymphoma/leukemia 2 (BCL-2) family of proteins has attracted the attention of cancer biologists since the cloning of BCL-2 more than 25 years ago. In the intervening decades, the way the BCL-2 family controls commitment to programmed cell death has been greatly elucidated. Several drugs directed at inhibiting BCL-2 and related antiapoptotic proteins have been tested clinically, with some showing considerable promise, particularly in lymphoid malignancies. A better understanding of the BCL-2 family has also provided insight into how conventional chemotherapy selectively kills cancer cells and why some cancers are more chemosensitive than others. Further exploitation of our understanding of the BCL-2 family promises to offer improved predictive biomarkers for oncologists and improved therapies for patients with cancer.
展开
关键词：
Animals Humans Sulfonamides Aniline Compounds Piperazines Pyrroles Antineoplastic Agents Proto-Oncogene Proteins c-bcl-2 Treatment Outcome Drug Resistance, Neoplasm
DOI：
10.1200/JCO.2011.37.0981
被引量：
年份：
2012
相似文献
参考文献
引证文献
引用走势
辅助模式
引用
文献可以批量引用啦~
欢迎点我试用！
